|Dr. Ivan Bergstein M.D.||Founder, Chairman and Chief Exec. Officer||937.32k||N/A||51|
|Mr. David G. Gionco||Chief Accounting Officer and VP of Fin.||441.88k||N/A||57|
|Mr. Kenneth Hoberman||Chief Operating Officer and Corp. Sec.||642.74k||N/A||52|
|Dr. Eric K. Rowinsky M.D.||Consultant||N/A||N/A||60|
Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercialization of proprietary oncology therapeutics in the United States. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which is in Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm, myeloproliferative neoplasms, and acute myeloid leukemia; and in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It also develops SL-801, a novel oral small molecule reversible inhibitor of a tumor-promoting nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that is in Phase II clinical trial to attack brain cancer. In addition, it develops SL-501, a next generation IL-3R-targeted therapy that is in preclinical development. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
Stemline Therapeutics, Inc.’s ISS Governance QualityScore as of December 1, 2017 is 7. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 8; Compensation: 6.